Momento de la terapia con Denosumab en relación con la paratiroidectomía en el contexto de hiperparatiroidismo primario: Informe de caso

and increased risk of vertebral fractures if denosumab is delayed or missed. Conversely, if denosumab is given in the periprocedural period, severe postsurgical hypocalcemia can result if denosumab prevents liberation of calcium from bone. Considering this, parathyroidectomy was performed 6 months after the last denosumab dose, and it was resumed 8 weeks after surgery. 1 month after surgery, calcium was normal, and PTH had recovered to mid-normal range. Her postoperative course was uncomplicated, and she was able to resume denosumab. Copyright © 2026 Ryan S. MacLeod et al. Case Reports in Endocrinology published